Skip to main content

DC-based immunotherapy to treat Malignant Mesothelioma


A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Autori: Robert A. Belderbos, Paul Baas, Rossana Berardi, Robin Cornelissen, Dean A. Fennell, Jan P. van Meerbeeck, Arnaud Scherpereel, Heleen Vroman, Joachim G. J. V. Aerts
Pubblicato in: Translational Lung Cancer Research, 8/3, 2019, Page(s) 280-285, ISSN 2218-6751
Editore: AME publishing company
DOI: 10.21037/tlcr.2019.05.05